CL2020003447A1 - Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas - Google Patents

Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas

Info

Publication number
CL2020003447A1
CL2020003447A1 CL2020003447A CL2020003447A CL2020003447A1 CL 2020003447 A1 CL2020003447 A1 CL 2020003447A1 CL 2020003447 A CL2020003447 A CL 2020003447A CL 2020003447 A CL2020003447 A CL 2020003447A CL 2020003447 A1 CL2020003447 A1 CL 2020003447A1
Authority
CL
Chile
Prior art keywords
compositions
methods
inflammasome
conditions
related diseases
Prior art date
Application number
CL2020003447A
Other languages
English (en)
Spanish (es)
Inventor
Robert W Keane
W Dalton Dietrich
Rivero Vaccari Juan Pablo De
Helen M Bramlett
Roberta Brambilla
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/026,482 external-priority patent/US10703811B2/en
Application filed by Univ Miami filed Critical Univ Miami
Publication of CL2020003447A1 publication Critical patent/CL2020003447A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CL2020003447A 2018-07-03 2020-12-30 Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas CL2020003447A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16/026,482 US10703811B2 (en) 2016-12-29 2018-07-03 Methods and compositions for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
CL2020003447A1 true CL2020003447A1 (es) 2021-07-30

Family

ID=78823964

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003447A CL2020003447A1 (es) 2018-07-03 2020-12-30 Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas

Country Status (16)

Country Link
US (1) US12570735B2 (enExample)
EP (1) EP3818081A4 (enExample)
JP (2) JP7824030B2 (enExample)
KR (1) KR20210071944A (enExample)
CN (1) CN113316588B (enExample)
AU (1) AU2019297515B2 (enExample)
BR (1) BR112020026798A2 (enExample)
CA (1) CA3105129A1 (enExample)
CL (1) CL2020003447A1 (enExample)
CO (1) CO2021001172A2 (enExample)
IL (1) IL279851A (enExample)
MX (1) MX2021000142A (enExample)
PH (1) PH12020552286A1 (enExample)
SG (1) SG11202013176VA (enExample)
WO (1) WO2020010273A1 (enExample)
ZA (2) ZA202100703B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240060995A1 (en) * 2012-02-06 2024-02-22 University Of Miami Innate immune proteins as biomarkers for traumatic brain injury in adult and pediatric patients
WO2018126009A1 (en) 2016-12-29 2018-07-05 University Of Miami Method for modulating inflammasome activity and inflammation in the lung
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
EP3818081A4 (en) 2018-07-03 2022-06-22 University of Miami COMPOSITIONS AND METHODS FOR TREATING INFLAMMASOME-RELATED DISEASES OR DISORDERS
US20230296626A1 (en) * 2020-04-27 2023-09-21 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions
EP4433167A1 (en) * 2021-11-16 2024-09-25 AC Immune SA Novel molecules for therapy and diagnosis
EP4583974A1 (en) * 2022-09-09 2025-07-16 University of Miami Inflammasome antibody compositon and method for treating neurologic disorder
WO2024114906A1 (en) * 2022-11-30 2024-06-06 Mabylon Ag Antibodies against apoptosis-associated speck-like protein containing a card (asc) and uses thereof
WO2026042013A1 (en) * 2024-08-19 2026-02-26 Institute Of Molecular And Clinical Ophthalmology Basel (Iob) Mitochondrial therapy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763849B1 (fr) 1997-05-28 2000-09-15 Rhone Poulenc Rorer Sa Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement des oedemes cerebraux
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
RU2407752C2 (ru) 2004-04-29 2010-12-27 Оцука Фармасьютикал Ко., Лтд. Антитела к гликопротеину vi и способы продуцирования и использования этих антител
WO2005111283A1 (ja) * 2004-05-17 2005-11-24 Denki Kagaku Kogyo Kabushiki Kaisha ポリ塩化ビニル繊維及びその製造方法並びに人工毛髪
KR20070094890A (ko) 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 안티 ａｄｄｌ 항체 및 그 용도
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
JP2009510105A (ja) 2005-09-28 2009-03-12 バイオバスキュラー インコーポレーティッド 血小板および細胞の接着、細胞移動、および炎症を阻止するための方法および組成物
SI3219328T1 (sl) 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
AU2007267561B2 (en) 2006-05-25 2012-05-17 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
KR20100014588A (ko) 2007-02-27 2010-02-10 제넨테크, 인크. 길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
US8685400B2 (en) 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
EP2300000A1 (en) * 2008-07-03 2011-03-30 University of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
EP2145624A1 (en) 2008-07-18 2010-01-20 Sanofi-Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
WO2011029931A1 (en) 2009-09-11 2011-03-17 Protaffin Biotechnologie Ag Composition for treatment of cxcl8-mediated lung inflammation
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
SMT202000095T1 (it) * 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
IT1406201B1 (it) 2010-12-10 2014-02-14 Univ Degli Studi Trieste Biomarcatori per la diagnosi della sclerosi multipla
ES2578477T3 (es) 2011-03-11 2016-07-27 Roche Diagniostics Gmbh ASC como marcador de la enfermedad pulmonar obstructiva crónica (EPOC)
WO2013049278A1 (en) 2011-09-30 2013-04-04 Novartis Ag USE OF IL-1 ß BINDING ANTIBODIES
WO2013119673A1 (en) 2012-02-06 2013-08-15 University Of Miami Innate immune proteins as biomarkers for cns injury
TWI480044B (zh) 2012-03-16 2015-04-11 Taichung Veterans General Hospital A high molecular weight heparin or low molecular weight heparin for the preparation of a composition for at least two consecutive days of administration to improve the allergic constitution
US20140314746A1 (en) * 2013-03-13 2014-10-23 Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine Methods for treating or preventing fibrosis in subjects afflicted with scleroderma
MX2015015784A (es) 2013-05-17 2016-03-11 Genentech Inc Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
JP6359013B2 (ja) * 2013-07-29 2018-07-18 国立大学法人 鹿児島大学 １，５−ｄ−アンヒドロフルクトースを含むアポトーシス関連スペック様カード蛋白質の機能阻害薬
JP7066321B2 (ja) 2014-01-10 2022-05-13 アヴァリン ファーマ インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
US10261098B2 (en) 2014-08-18 2019-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for diagnosis and management of neuro-immunological diseases
CA2964315A1 (en) 2014-10-16 2016-04-21 Novartis Ag Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
US20160263183A1 (en) 2015-03-10 2016-09-15 Brown University Methods for treating lung disease
CN114181281A (zh) 2015-05-12 2022-03-15 加利福尼亚大学董事会 用于炎症和纤维化的肽治疗
JP6887987B2 (ja) 2015-08-17 2021-06-16 ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ
KR101948048B1 (ko) 2016-12-08 2019-02-14 한양대학교 에리카산학협력단 톡소포자충 ｇｒａ７ 항원 유래 재조합 단백질을 유효성분으로 포함하는 결핵 예방 또는 치료용 약학 조성물
WO2018126009A1 (en) 2016-12-29 2018-07-05 University Of Miami Method for modulating inflammasome activity and inflammation in the lung
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
US10755739B1 (en) 2016-12-30 2020-08-25 John Fristrom Remote railway crossing programmable device and methods thereof
CN111356924A (zh) 2017-09-20 2020-06-30 迈阿密大学 检测作为神经障碍生物标记的炎性体蛋白的方法
EP3818081A4 (en) 2018-07-03 2022-06-22 University of Miami COMPOSITIONS AND METHODS FOR TREATING INFLAMMASOME-RELATED DISEASES OR DISORDERS

Also Published As

Publication number Publication date
JP7824030B2 (ja) 2026-03-04
SG11202013176VA (en) 2021-01-28
CN113316588A (zh) 2021-08-27
CA3105129A1 (en) 2020-01-09
AU2019297515B2 (en) 2026-06-04
KR20210071944A (ko) 2021-06-16
JP2025067915A (ja) 2025-04-24
CN113316588B (zh) 2025-02-28
CO2021001172A2 (es) 2021-07-09
JP7850296B2 (ja) 2026-04-22
MX2021000142A (es) 2021-05-12
EP3818081A4 (en) 2022-06-22
ZA202201437B (en) 2024-05-30
PH12020552286A1 (en) 2021-06-21
AU2019297515A1 (en) 2021-02-25
US20210284723A1 (en) 2021-09-16
WO2020010273A1 (en) 2020-01-09
US12570735B2 (en) 2026-03-10
ZA202100703B (en) 2022-08-31
JP2021528092A (ja) 2021-10-21
IL279851A (en) 2021-03-01
BR112020026798A2 (pt) 2021-03-30
EP3818081A1 (en) 2021-05-12

Similar Documents

Publication Publication Date Title
CO2021001172A2 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
CO2019008087A2 (es) Método para modular la actividad de inflamasoma e inflamación en el pulmón
MX2022014548A (es) Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
MX2021009673A (es) Moduladores de ror-gamma.
CL2019002895A1 (es) Inhibidores de pd-1/pd-l1.
CL2020002019A1 (es) Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582)
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
CO2019002371A2 (es) Adenovirus armado con captador biespecífico de linfocitos t (bite)
CL2021001027A1 (es) Inhibidores selectivos de rgmc y el uso de los mismos
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX389460B (es) Composiciones y metodos de uso en nintedanib para tratar enfermedades oculares con neovascularizacion anormal.
UY37391A (es) Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
UY37098A (es) Moduladores de ror-gamma
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX388380B (es) Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
MX2017014818A (es) Agonistas de triazol del receptor apj.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
PE20170140A1 (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
CO2018001421A2 (es) Composición y productos que comprenden células senescentes para su uso en la regeneración de tejidos
MX2019000428A (es) Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori.
PE20180691A1 (es) Variantes de il-37
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2